Pharmaceuticals

Obagi Medical Products, Inc. (Nasdaq: OMPI) announced the publication of a study showing that the use of its Condition & Enhance System (also marketed as Nu-Derm), when combined with Botulinum Toxin Type A treatments (BOTOX®), provides greater improvement in overall facial appearance, as well...

Forest Laboratories, Inc. (NYSE: FRX) today announced that IVS Associates, Inc., the independent inspector of elections, has certified the final voting results for the Company's Annual Meeting, which was held on August 18, 2011. The certified results, which are consistent with the preliminary...

Morgan Keegan downgraded Abbott Laboratories (NYSE: ABT) from “outperform” to “market perform.” ABT's shares closed at $50.51 yesterday. Abbott Laboratories' trailing-twelve-month ROA is 8.03%. Pacific Sunwear of California Inc (NASDAQ: PSUN) was downgraded by Oppenheimer from "outperform" to "...

Pre-open movers US stock futures are lower this morning, as investors are awaiting data on demand for durable goods. Futures for the Dow Jones Industrial Average dipped 99 points to 11,042.00 and S&P 500 index futures fell 10.60 points to 1,148.00. Nasdaq 100 futures dropped 18.50 points to 2,...

Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it entered into a definitive agreement to acquire Anchen Pharmaceuticals, for $410 million in cash.  The transaction is expected to be immediately accretive to non-GAAP earnings in 2011.

Piper Jaffray has published a research report on Salix Pharmaceuticals (NASDAQ: SLXP) reporting largely positive outcomes. In the report, Piper Jaffray wrote, "A key reason for the weakness in our view, aside from weakness in the broader markets, is a general Street view that Xifaxan in irritable...

Morgan Keegan has downgraded Abbott Laboratories (NYSE: ABT) from Outperform to Market Perform and has lowered the price target from $60 to $57.

Credit Suisse has upgraded Elan Corporation (NYSE: ELN) from Neutral to Outperform.

The Problem A spate of frightening headlines has led to two troubling declines in financial instruments.  The first, of course, is the decline in equity prices that has everyone worried about their financial futures.  This drop in stock price is in everybody's face and therefore commands prime time...

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced today that it has filed a Notice of Intention to make a normal course issuer bid with The Toronto Stock Exchange and that the TSX has accepted the Notice of Intention. Under the bid, the Company will have the right to purchase for...

CEL-SCI Corporation (NYSE: CVM) today announced that it has entered into an exclusive Sales, Marketing and Distribution agreement with IDC-GP Pharm LLC under which CEL-SCI has granted IDC-GP Pharm an exclusive license to market and distribute the Company's investigational cancer therapy, Multikine...

VIVUS, Inc. (NASDAQ: VVUS) today announced that it has entered into definitive agreements dated August 23, 2011 with a select group of institutional investors to sell 6,889,098 shares of its common stock in a "registered direct" offering. The investors have agreed to purchase the shares at a...

First Global Research has published a research report on Pfizer Inc (NYSE: PFE). In the report, First Global wrote, "Pfizer Inc. (PFE) delivered a respectable performance for Q2 CY11 that met our expectations. The company's non-GAAP EPS of 60 cents for the quarter came in line with our estimate,...

Deutsche Bank is out with a research report on Medicis Pharmaceutical (NYSE: MRX) and it has a Buy rating and a $40 price target on shares. In a note to clients, Deutsche Bank writes, "We recently hosted a day of investor meetings with management. Following these meetings, we maintain our Buy...

Forest Laboratories (NYSE: FRX) today announced that the preliminary report of IVS Associates, the independent inspector of elections for the Company's Annual Meeting, confirms that all ten of Forest's Board nominees were elected by a substantial majority. Based on the IVS report of the...